Testosterone Litigation | 2015 Low T Lawsuits Status Update

gelWith roughly 300 complaints currently pending before U.S. District Judge Mathew Kennelly, and several thousand expected to be filed before all is said and done, Judge Kennelly of the Northern District of Illinois has appointed four testosterone drug attorneys to serve as liaisons with state courts where dozens of additional cases are pending.  In an effort to increase coordination of the litigation, the role of the state-federal court liaisons will be to promote better coordination for the rapidly accumulating host of testosterone lawsuits  being filed.

What’s It All About?

Testosterone products, prescribed to treat low testosterone (“Low T”) in men, have become popular among young men seeking physical enhancement, as well as older men who want to counter signs of aging.  The problem?  In simple terms, low testosterone treatments may double the risk of heart attack for young men with heart disease as well as for men 65 years of age and older, even those who have had no heart problems.  Recent concerns include the increased risk of deep vein thrombosis (DVT) which can lead to life-threatening complications including pulmonary embolisms.  DVT is where the body develops blood clots in the deep veins, most commonly in the legs. These blood clots can break off and travel through the body resulting in potentially life-threatening complications. But there is growing concern that these products have serious side effects and long-term risks, particularly related to the heart.

Men who have used one or more of these supplements or low testosterone products, who then suffer cardiac arrest, stroke, other heart-related issues and side effects are beginning to file lawsuits contending they were not properly warned of the risks.  All of the complaints involve nearly identical allegations that these products caused heart attack, stroke, pulmonary embolism, DVT, or other injuries.

Lawsuit Status

The lawsuits name products such as Androgel, Axiron, Testim, Androderm, and Depo-Testosterone, though the majority of the cases filed involve Androgel. Manufactured by AbbVie Inc., a drugmaker that spun off Abbott Laboratories in 2013, Androgel has 60% of the testosterone replacement therapy market.  With this in mind, Judge Kennelly has outlined a case management plan for Androgel, separate from that which will guide litigation against the other defendants.

In a case management order issued on December 19th, Judge Kennelly indicated that a group of non-Androgel cases will prepare for early trial dates, known as bellwether lawsuits, to go before a jury in mid-2017.  Slightly further along, the first Androgel trials are expected to begin by late 2016.  Bellwether lawsuits, common in complex pharmaceutical litigation, are designed to help the parties gauge how juries may respond to certain evidence and testimony, as well as reduce duplicative discovery common to the lawsuits, and avoid conflicting pretrial rulings from different judges.  While not binding on other claims, the process hopefully helps to facilitate settlements and avoid the need for individual trials.  Should that not happen, the cases may be remanded back to the U.S. District Court where the case was initially filed for an individual trial date.

Contact Us

These are very unfortunate cases.  We believe that these products should have warned of these risks. If you or a loved one has suffered a heart attack, stroke, pulmonary embolism, DVT, or any other injury related to the use of one or more of these low testosterone products, contact us now.  Whether you are ready to file suit, or are just looking for additional information, our team can help you get answers and guide you thought the challenges you face.  Contact us at 1.800.553.8082 or online here.

Updated: